News
Keep up with Ology Bioservices. Here’s our latest…
News
Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases
Barrett PN, Terpening SJ, Snow D, Cobb RR, Kistner O. Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases. Expert Review of Vaccines. 2017;16(9):883-894. Read More > [...]
Development of a synthetic Vi polysaccharide vaccine for typhoid fever
Ni Y, Springer MJ, Guo J, et al. Development of a synthetic Vi polysaccharide vaccine for typhoid fever. Vaccine. 2017;35:7121–7126. Read Here >
An ambient temperature-stable anti toxin of nine co-formulated antibodies for botulism caused by serotypes A, B and E
Li M, Lee D, Obi CR, Freeberg JK, Farr-Jones S, Tomic MT. An ambient temperature-stable anti toxin of nine co-formulated antibodies for botulism caused by serotypes A, B and E. PLoSONE 2018.13(5):e0197011. Read Here > [...]
Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder.
Ball JP, Springer MJ, Ni Y, Finger-Baker I, Martinez J, Hahn J, et al. Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder. PLoSONE. 2017;12(5):e0177310 Read Here > [...]
Ology Bioservices and RAFA Laboratories Announce FDA Approval of the Atropine Autoinjector
Ology Bioservices and RAFA Laboratories Announce FDA Approval of the Atropine Autoinjector as a Medical Countermeasure for Chemical Nerve Agents ALACHUA, Fla. & JERUSALEM--(BUSINESS WIRE)--Ology Bioservices, Inc., a biologics contract development and [...]
Ology Bioservices to Develop Vaccine Candidate Against Malaria for The Global Health Initiative Fund
Ology Bioservices will develop the large-scale, process development and manufacturing plan and supply the AnAPN1 vaccine candidate for use in ongoing pre-clinical studies and to prepare for subsequent clinical testing.